Jaguar Health Surges as FDA Fee Waivers and Tiny Post-Split Float Drive Volatility

By: Quiver PriceTracker

Posted: 49 minutes ago / Sept. 22, 2026 9:20 p.m. UTC

JAGX

Jaguar Health (JAGX) is up 1585.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The biggest identifiable catalyst appears to be Jaguar’s September 22 announcement that it received FDA fee waivers tied to Mytesi and Canalevia-CA1, which may have improved sentiment around cash needs and its drug portfolio. The move also looks amplified by technical factors after the company’s recent 1-for-15 reverse split, which left a very small post-split share count and likely made the stock more prone to sharp momentum swings.

Details:

Jaguar said Napo received a waiver of the 2027 Prescription Drug User Fee Act fee for Mytesi, while Jaguar also received a 2027 FDA veterinary fee waiver for Canalevia-CA1.

The same company update said management remains focused on its rare-disease intestinal failure program and is targeting a mid-2027 NDA filing for crofelemer in microvillus inclusion disease.

Jaguar previously announced a 1-for-15 reverse stock split that became effective on September 17, 2026, primarily to support compliance with Nasdaq listing standards.

A September 21 filing stated that, after the reverse split, Jaguar had about 520,088 shares outstanding, a setup that can intensify price swings and contributed to repeated volatility pauses during today’s session.

Sources:

Jaguar Health, SEC, Nasdaq Trader

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$JAGX Hedge Fund Activity

We have seen 3 institutional investors add shares of $JAGX stock to their portfolio, and 10 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DRW SECURITIES, LLC removed 17,823 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,603
XTX TOPCO LTD removed 12,451 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,613
GEODE CAPITAL MANAGEMENT, LLC removed 3,146 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $9,438
SBI SECURITIES CO., LTD. removed 2,487 shares (-96.7%) from their portfolio in Q2 2026, for an estimated $7,461
TOWER RESEARCH CAPITAL LLC (TRC) added 1,094 shares (+1657.6%) to their portfolio in Q2 2026, for an estimated $3,282
UBS GROUP AG added 774 shares (+24.0%) to their portfolio in Q2 2026, for an estimated $2,322
HRT FINANCIAL LP removed 434 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,302

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.